Andrew Scarborough is one of the IBTA’s Editors and is based in the United Kingdom. He is a cancer researcher, podcaster and passionate patient advocate, currently working to support Health Education England’s Cancer and Diagnostics team to meet key deliverables following challenges presented by the COVID-19 pandemic.
Andrew has spoken on several platforms about research into metabolic therapies and has detailed his personal experiences on the potential of novel compounds to manage brain tumour related epilepsy (BTRE).
In 2013, while studying for a Masters degree in Nutritional Therapy at the University of Westminster, Andrew suffered a brain haemorrhage which revealed an underlying anaplastic astrocytoma brain tumour. Following this devastating diagnosis, Andrew realised there were few options to treat the disease beyond the standard of care.
Andrew’s experiences sparked an interest in investigating why brain tumours are so difficult to treat, returning to higher education to study with a focus on cancer biology.
Commencing these studies with a BSc in Human and Medical Science, he gained further experience in a brain tumour research laboratory at Imperial College London, before going on to postgraduate study in Clinical Bioinformatics with the University of Manchester. In future Andrew aims to return to the laboratory environment to complete a PhD once he has achieved personal performance targets with Health Education England.
Andrew has a great appreciation for science communication and how the IBTA provides hope to patients, carers and health professionals. It is his belief that raising awareness of emerging treatments, clinical trials and evidence-based research empowers patients and provides us all with promise for a better future.
BACK TO IBTA TEAM
